GENOME MEDICAL, INC.
SOUTH SAN FRANCISCO, CA

GENOME MEDICAL NAVIGATOR According to medical guidelines, all women of reproductive age should be offered a screening test—before pregnancy—for genetic conditions that can be passed on. GENOME MEDICAL NAVIGATOR Genome Medical is not currently a participating provider with any health insurance plan. However, a consultation may be a covered service under your insurance. We will collect your insurance information and submit a claim to your insurance company on your behalf. Genome Medical offers a discount for self-pay patients. If you choose self-pay (not insurance billing), the cost is $179 per session. This would be billed to you after your appointment. What is the difference between Option 1 (insurance) and Option 2 (self-payment)? With Option 1, you are using your health insurance benefits to pay for the claim. Due to the uncertainty of insurance reimbursement, Genome Medical collects the payment upfront and reimburses you after the insurance company has paid. This could reduce your responsibility. Option 2 is a discounted self-pay price. Additional payment plans and financial assistance programs are available; please talk to a Genome Medical care coordinator for details. To get started, close this window and contact a Genome Medical care coordinator by chat or phone. The care coordinator will explain your options, take your insurance information (if necessary), help you schedule an appointment and answer your questions. GENOME MEDICAL NAVIGATOR According to medical guidelines, all women of reproductive age should be offered a screening test—before pregnancy—for genetic conditions that can be passed on. GENOME MEDICAL NAVIGATOR Genome Medical is not currently a participating provider with any health insurance plan. However, a consultation may be a covered service under your insurance. We will collect your insurance information and submit a claim to your insurance company on your behalf. Genome Medical offers a discount for self-pay patients. If you choose self-pay (not insurance billing), the cost is $179 per session. This would be billed to you after your appointment. What is the difference between Option 1 (insurance) and Option 2 (self-payment)? With Option 1, you are using your health insurance benefits to pay for the claim. Due to the uncertainty of insurance reimbursement, Genome Medical collects the payment upfront and reimburses you after the insurance company has paid. This could reduce your responsibility. Option 2 is a discounted self-pay price. Additional payment plans and financial assistance programs are available; please talk to a Genome Medical care coordinator for details. To get started, close this window and contact a Genome Medical care coordinator by chat or phone. The care coordinator will explain your options, take your insurance information (if necessary), help you schedule an appointment and answer your questions. In a time of unparalleled advancement in genetic research, many people have yet to access the benefits of genomic medicine. Genome Medical was created to change that, by ensuring the lifelong journey of genomic medicine becomes accessible to everyone. We are a nationwide genomics medical practice bringing genetics to everyday life. Our clinical team provides expert genetic health care for individuals and families to improve health and well-being. We also help clinicians and patients navigate the rapidly expanding field of genetic testing and use test results to understand disease risk, speed diagnosis, make informed treatment decisions and lower the cost of care. Genome Medical was founded in 2016 by genetics industry leaders Lisa Alderson, MBA; Randy Scott, PhD, executive chairman of Invitae and founder of Genomic Health; and Robert C. Green, MD, MPH, a medical geneticist who directs the Genomes2People Research Program at Brigham and Women’s Hospital, is an associate member of the Broad Institute and is professor of medicine at Harvard Medical School. Lisa has 20 years of experience building early-stage companies with a focus on technology, consumer and life sciences businesses. Prior to Genome Medical, Lisa served as the Chief Commercial Officer and Chief Strategy Officer of Invitae (NYSE: NVTA), a rapidly growing genetic information company. She was part of the start-up team at Genome Health Inc. (Nasdaq: GHDX), president of Cinema Circle Inc. and the former manager of strategic planning at The Walt Disney Co. Randy is Chairman of Invitae, a company he co-founded and where he previously served as CEO. He also founded Genomic Health and served as Genomic Health’s Chief Executive Officer from 2000 until 2009 and Executive Chairman until 2012. Under Randy’s leadership, Genomic Health developed and launched two revolutionary cancer diagnostics tests. At Incyte, Randy served in various roles from 1991 through 2000, including Chairman of the Board, President and Chief Scientific Officer. Dr. Green is co-founder and chairman of Genome Medical’s Scientific Advisory Board. He is a medical geneticist and physician-scientist who directs the G2P Research Program in translational genomics and health outcomes in the Division of Genetics at Brigham and Women’s Hospital and Harvard Medical School. Dr. Green is principal investigator of the MedSeq Project, the first NIH-funded randomized trial to explore the use of whole genome sequencing in the clinical practice of medicine. Lisa has 20 years of experience building early-stage companies with a focus on technology, consumer and life sciences businesses. Prior to Genome Medical, Lisa served as the Chief Commercial Officer and Chief Strategy Officer of Invitae (NYSE: NVTA), a rapidly growing genetic information company. She was part of the start-up team at Genome Health Inc. (Nasdaq: GHDX), president of Cinema Circle Inc. and the former manager of strategic planning at The Walt Disney Co. Sandra has more than 20 years in finance and strategy for venture-backed companies. Prior to Genome Medical, she served as interim CFO for Glooko, a diabetes information management SaaS solution. Previously, as CFO, she ushered two consecutive biotech companies from start-up to acquisition by public companies (Ligand Pharmaceuticals (NASDAQ: LGND and Roche Holdings AG “RHHBY”).